Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)

Inclusion Criteria: * Be male aged 45 or older. * Sign an informed consent form. * Be in good health. * Received NX-1207 in a previous completed study (other than NX02-0020) or received NX-1207 or placebo in a concurrent U.S. study (NX02-0017 and NX02-0018) and completed their V10 (365 day) visit. * Have Prostate Gland Volume ≥ 25 mL (25 g). Exclusion Criteria: * Surgery or minimally invasive surgical therapy (MIST) for treatment of BPH after first NX-1207 injection * Post-void residual urine volume \> 200 mL * Presence of a symptomatic median lobe of the prostate * History of use of self-catheterization for urinary retention. * Urinary retention in the previous 12 months. * Prostatitis * Urinary tract infection more than once in the past 12 months * Prostate or bladder cancer. * Prostate-Specific Antigen (PSA) ≥ 10 ng/mL * Poorly controlled diabetes * History or evidence of illness or condition that may interfere with study or endanger subject * Participation in a study of any investigational drug (other than NX-1207) or investigational device within the previous 90 days * Use of specific prescribed medications that may interfere with study or endanger subject